A tannic extract for oral and topical treatment of CVI and haemorrhoids

P. Rohdewald

doi:10.1055/s-0037-1621484

Phlebologie, Inhaltsverzeichnis

Phlebologie 2015; 44(06): 334-337
DOI: 10.1055/s-0037-1621484

Review Article

Schattauer GmbH

Gerbstoffhaltiger Extrakt zur oralen und topischen Behandlung bei CVI und Hämorrhoidalleiden

Artikel in mehreren Sprachen: English | deutsch

P. Rohdewald

¹Institut für Pharmazeutische Chemie, Westfälische-Wilhelms-Universität, Münster, Germany

› Institutsangaben

Abstract

Zusammenfassung

Die vorliegende Literaturübersicht fasst Untersuchungen zu den biologischen und klinischen Wirkungen eines Extraktes aus der Rinde der französischen Meereskiefer (Pycnogenol^®) bei der chronischen Veneninsuffizienz (CVI) zusammen.

Ursachen der anti-ödematösen und anti-thrombotischen Wirkungen sind die Verbesserung der Endothelfunktion, die Hemmung der Permeabilität der Kapillarwände und der Thrombozytenaggregation. Des Weiteren trägt die anti-inflammatorische und anti-oxidative Wirkung zur beschleunigten Heilung von Ulzera und Hämorrhoidalleiden nach oraler und kutaner Anwendung von Pycnogenol^® bei. Die Hemmung der Ödeme der unteren Gliedmaßen und der Entstehung von tiefen Thrombosen wurde auch bei Passagieren von Langstreckenflügen nachgewiesen. In vergleichenden Untersuchungen konnte die Überlegenheit von Pycnogenol^® gegenüber einigen Venotonika und der Anwendung von medizinischen Kompressionsstrümpfen gezeigt werden. Milde, unerwünschte Wirkungen traten bei etwa 1 % der Fälle auf.

Schlüsselwörter

Pycnogenol^® - Ödeme - Ulzera - Thrombosen - CVI - Hämorrhoidalleiden

Volltext

Referenzen

References
1 Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J. Clin Pharmacol Ther 2002; 40 (Suppl. 04) 158-168.
2 Nishioka K, Hidaka T, Nakamura S. et al. Pycnogenol®, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res 2007; 30: 775-780.
3 Liu X, Wei J, Tan F. et al. Antidiabetic effect of Pycnogenol® French maritime pine bark extract in patients with diabetes type II. Life Sci 2004; 75 (Suppl. 21) 2505-2513.
4 Cesarone MR, Belcaro G, Rohdewald P. et al. Rapid relief of signs/symptoms in chronic venous microangiopathy with Pycnogenol®: A prospective, controlled study. Angiology 2006; 57 (Suppl. 05) 569-576.
5 Belcaro G, Cesarone MR, Errichi BM. et al. Venous ulcers: Microcirculatory improvement and faster healing with local use of Pycnogenol. Angiology 2005; 56 (Suppl. 06) 699-705.
6 Rohdewald PJ. Pycnogenol®, French Maritime Pine Bark Extract. In: Encyclopedia of Dietary Supplements. Marcel Dekker Inc.; NY: 2005: 545-553.
7 Grimm T, Chovanova Z, Muchova J. et al. Inhibition of NF- B activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). Journal of Inflammation 2006; 3: 1.
8 Schäfer A, Chovanova Z, Muchova J. et al. Inhibition of Cox-1 and Cox-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother 2005; 60 (Suppl. 01) 5-9.
9 Canali R, Comitato R, Schönlau F, Virgili F. The anti-inflammatory pharmacology of Pycnogenol® in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. Int Immunopharmacol 2009; 9: 1145-1149.
10 Lau BHS, Riesen SK, Truong KP. Pycnogenol® as an adjunct in the management of childhood Asthma. J Asthma 2004; 41 (Suppl. 08) 825-832.
11 Grimm T, Schäfer A, Högger P. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (Pycnogenol). Free Radic Biol Med 2004; 36 (Suppl. 06) 811-822.
12 Marini A, Grether-Beck S, Jaenicke T. et al. Pycnogenol® effects on skin elasticity and hydration coincide with increased gene expressions of collagen Type I and hyaluronic acid synthase in women. Skin Pharmacol Physiol 2012; 25: 86-92.
13 Gabor M, Engi E, Sonkodi S. Die Kapillarwandresistenz und ihre Beeinflussung durch wasserlösliche Flavonderivate bei spontan hypertonischen Ratten. Phlebologie 1993; 22: 178-182.
14 Belcaro G, Hu S, Cesarone MR, Dugall M. A controlled study shows daily intake of 50mg Pycnogenol significantly lowers plasma reactive oxygen metabolites in 155 healthy smokers. Minerva Med 2013; 104: 439-446.
15 Errichi S, Bottari A, Belcaro G. et al. Supplementation with Pycnogenol® improves signs and symptoms of menopausal transition. Panminerva Med 2011; 53 Suppl. 1, to N°3 65-70.
16 Belcaro G, Dugall M, Luzzi R. et al. Improvement of Venous Tone with Pycnogenol in Chronic Venous Insufficiency: An Ex Vivo Study on Venous Segments. Int J Angiol 2014; 23: 47-52.
17 Schmidtke I, Schoop W. Das hydrostatische Ödem und seine medikamentöse Beeinflussung. Swiss Med 1984; 6 4a 67-69.
18 Arcangeli P. Pycnogenol® in chronic venous insufficiency. Fitoterapia 2000; 71 (Suppl. 03) 236-244.
19 Petrassi C, Mastromarino A, Spartera C. Pycnogenol® in chronic venous insufficiency. Phytomedicine 2000; 7 (Suppl. 05) 383-388.
20 Belcaro G, Cesarone MR, Ricci A. et al. Control of edema in hypertensive subjects treated with calcium antagonist nifedipine) or angiotensin-converting enzyme inhibitors with Pycnogenol. Clin Appl Thromb Hemost 2006; 12 (Suppl. 04) 440-444.
21 Koch R. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency. Phytother Res 2002; 16: S1-S5.
22 Cesarone MR, Belcaro G, Rohdewald P. et al. Comparison of Pycnogenol and Daflon in Treating Chronic Venous Insufficiency: A prospective, Controlled study. Clin Appl Thromb Hemost 2006; 12 (Suppl. 02) 205-212.
23 Riccioni C, Sarcinella R, Izzo A. et al. Efficacy of Troxerutine in association with Pycnogenol in the treatment of venous insufficiency. Eur Bull Drug Res 2004; 12 (Suppl. 01) 7-12.
24 Belcaro G. A clinical comparison of Pycnogenol, Antistax, and stockings in chronic venous insufficiency. Int J Angiol. 2015 DOI: dx.doi.org/10.1055/s-0035–1556060.
25 Belcaro G, Cesarone MR, Errichi B. et al. Pycnogenol® treatment of acute hemorrhoidal episodes. Phytother Res 2010; 24 (Suppl. 03) 438-444.
26 Belcaro G, Dugall M, Luzzi R. et al. Postpartum varicose veins: Supplementation with Pycnogenol or elastic compression – A 12-month follow-up. Int J Angiol. 2014 DOI 10.1055/s-0033–1363784.
27 Cesarone MR, Belcaro G, Rohdewald P. et al. Improvement of signs and symtpoms of chronic venous insufficiency and microangiopathy with Pycnogenol®: A prospective, controlled study. Phytomedicine 2010; 17: 835-839.
28 Ericchi B, Belcaro G, Hosoi M. et al. Prevention of post-thrombotic syndrome with Pycnogenol®: A 12 month study. Panminerva Med 2011; 53 Suppl. 1, to N°3 21-27.
29 Belcaro G, Cesarone MR, Rohdewald P. et al. Prevention of venous thrombosis and thrombophlebitis in long-haul flights with Pycnogenol. Clin Appl Thromb Hemost 2004; 10 (Suppl. 04) 373-377.
30 Cesarone MR, Belcaro G, Rohdewald P. et al. Prevention of edema in long flights with Pycnogenol®. Clin Appl Thromb Hemost 2005; 11 (Suppl. 03) 289-294.
31 Belcaro G, Cesarone MR, Errichi BM. et al. Diabetic Ulcers: Microcirculatory improvement and faster healing with Pycnogenol. Clin Applied Thromb Hemost 2006; 12 (Suppl. 03) 318-323.
32 Blazso G, Gabor M, Schönlau F, Rohdewald P. Short communication: Pycnogenol® accelerates wound healing and reduces scar formation. Phytother Res 2004; 18 (Suppl. 07) 579-581.
33 Calvo Torras MA, Faura CA, Schönlau F, Rohdewald P. Short Communication: Antimicrobial activity of Pycnogenol®. Phytother Res 2005; 19: 647-648.